Next Article in Journal
Dietary Intake of Adolescents and Alignment with Recommendations for Healthy and Sustainable Diets: Results of the SI.Menu Study
Previous Article in Journal
Calcifediol or Corticosteroids in the Treatment of COVID-19: An Observational Study
Previous Article in Special Issue
Effect of Tempeh and Daidzein on Calcium Status, Calcium Transporters, and Bone Metabolism Biomarkers in Ovariectomized Rats
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 16
Issue 12
10.3390/nu16121911
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Relationships between Premenstrual Syndrome (PMS) and Diet Composition, Dietary Patterns and Eating Behaviors

by
Paulina Oboza
1,
Natalia Ogarek
1,
Mariusz Wójtowicz
2,
Tahar Ben Rhaiem
3,
Magdalena Olszanecka-Glinianowicz
4 and
Piotr Kocełak
1,*
1
Pathophysiology Unit, Department of Pathophysiology, Faculty of Medical Sciences, Medical University of Silesia, 40-055 Katowice, Poland
2
Clinical Department of Gynecology and Obstetrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland
3
Clinical Department of Obstetrics, Gynecology and Gynecological Oncology in Kędzierzyn-Koźle, Faculty of Medicine, Medical University, 45-052 Opole, Poland
4
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland
*
Author to whom correspondence should be addressed.
Nutrients 2024, 16(12), 1911; https://doi.org/10.3390/nu16121911
Submission received: 4 April 2024 / Revised: 12 May 2024 / Accepted: 7 June 2024 / Published: 17 June 2024
(This article belongs to the Special Issue Effects of Nutrition, Malnutrition and Excess Body Weight on Gynecological Disorders)
Browse Figure
Versions Notes

Abstract

:
Premenstrual Syndrome (PMS) is a disorder between gynecology and psychiatry which includes cognitive, affective, and somatic symptoms from mild to severe. The most severe form of PMS is premenstrual dysphoric disorder (PMDD) and it is considered a form of depressive disorder. An association between diet composition and the occurrence of PMS and its severity have been suggested. As such, this manuscript discusses the relationships between diet composition, dietary patterns and eating behaviors, and PMS. PubMed, Embase, Cochrane, and Web of Science databases were searched for related studies up to 18 January 2024. A text search with the following keywords singly or in combination was conducted: “Premenstrual syndrome”, “Nutrition”, “Diet composition”, “Dietary patterns”, and “Eating behaviors”. Studies published so far showed that low intake of simple carbohydrates, fats, salt, and alcohol, and high of fresh, unprocessed foods rich in B vitamins, vitamin D, zinc, calcium, and omega-3 fatty acids may help prevent the onset of PMS and reduce the severity of its symptoms. However, further studies are needed to formulate definitive recommendations for the use of vitamins, micronutrients and other dietary ingredients supplementation in women with PMS to improve functioning, overall well-being, and physical health. Large, randomized, double-blind clinical trials across diverse populations are necessary to formulate clear recommendations for supplementation in women with PMS.

1. Introduction

There is no universally accepted definition of premenstrual syndrome (PMS). It consists of both gynecological and psychiatric domains. The existing definitions remain incomplete and fragmented [1,2]. One commonly accepted definition characterizes PMS as a predictable, cyclic symptom cluster occurring in the luteal phase of the menstrual cycle, significantly disrupting various aspects of daily life [3]. The diagnostic criteria for PMS from the American College of Obstetricians and Gynecologists (ACOG) include the emergence of symptoms within five days before menstruation in at least three consecutive menstrual cycles and their resolution within four days after menstruation commences [2]. The ACOG proposes a definition of PMS to include both physical and psychiatric symptoms. However, this definition does not include the potential exacerbation of pre-existing disorders such as depression or panic disorder. In turn, the American Psychiatric Association (APA) definition of PMS focuses solely on psychiatric symptoms and explicitly excludes a diagnosis if the symptoms are exacerbations of another disease. Similarly, the World Health Organization (WHO) definition focuses on mental symptoms and classifies PMS in the International Classification of Diseases (ICD)-10 as Premenstrual Tension Syndrome. These different criteria create difficulties in diagnosing PMS. Moreover, it may be the cause of an underestimation of the severity of the disease. While rigorous use of the DSM-V criteria may result in a lack of diagnosis and inadequate treatment of women with significant dysfunction related to PMS [4]. Nevertheless, despite the inconsistencies in the PMS diagnostic criteria, treatment guideline recommendations include lifestyle changes, nonpharmacological interventions, and pharmacological, and surgical treatment [5,6,7].
A meta-analysis assessing the epidemiology of PMS showed a cumulative incidence of approximately 47.8% among women worldwide (95% CI: 32.6–62.9) [8]. Moreover, other meta-analyses revealed an overall prevalence of PMS of 48%, including 40% in Europe, 85% in Africa, 46% in Asia, and 60% in South America [9]. Furthermore, it has been shown that the pooled prevalence of PMS in Africa was 46.98% (95% CI: 28.9–65.06%) [10]. In addition, studies conducted in Europe showed the occurrence of PMS in 32.1% of Bulgarian and 31.9% of Italian women, and PMDD in 3.3% of Bulgarian women [11,12]. In contrast, a significantly lower occurrence of PMS 7.0% was observed among Korean women, with a gradual increase of approximately 1% per year during 8-year follow-up [13]. A higher occurrence of PMS was shown among young Arab women compared to European women. Seventy-seven per cent (77.7%) of Egyptian women, (72.9%) of Jordanian women, and (66.3%) of Syrian women, with PMDD observed in 40%, 34.7%, and 28.2% respectively [8]. Furthermore, in a cohort of Turkish women aged 18–25 years, PMS was found in 49.2%, and PMDD in 48.0% [14].
PMS symptoms include increased appetite, weight gain, abdominal and back pain, headaches, breast tenderness, nausea, constipation, anxiety, irritability, fatigue, mood swings, and tearfulness and the severity of symptoms may vary [15]. Premenstrual Dysphoric Disorder (PMDD) is one of the most severe forms of PMS. PMDD is included in the DSM-5, in the spectrum of depressive disorders. It is characterized by cognitive, affective, and somatic symptoms [2,16].
The pathogenesis of PMS remains unclear. Changes in sex steroid levels, especially progesterone, and in central neurotransmitters including serotonin, gamma-aminobutyric acid (GABA), glutamate, and beta-endorphins, play an important role in PMS pathogenesis [17]. In addition to family predispositions, diet and nutritional deficiencies can participate in the development of PMS [18]. It has also been shown that an increase in BMI of 1 kg/m2 is associated with a 3% increase in the risk of PMS development [19]. However, an association between PMS and being underweight was also shown (HR = 1.21, 95% CI 1.10–1.25) [20].
The associations between diet composition and the occurrence of PMS and its severity were suggested in some studies. In addition, changes in dietary patterns and eating behaviors were observed in women with PMS. Therefore, the aim of this manuscript is to analyze the available data on the relationship between PMS and diet composition, dietary patterns, and eating behaviors.

2. Changes in Energy and Macronutrient Intake during the Menstrual Cycle

Total energy intake fluctuated during the menstrual cycle. The highest intake was observed during the luteal phase in animal models [21] and human studies [22,23]. These changes can be explained by the different effects of estradiol and progesterone on hunger and appetite. Estradiol directly inhibits food intake and increases energy expenditure [24], while progesterone stimulates food intake [25]. Estradiol acts directly on anorexigenic and orexigenic neurons in the hypothalamus and brainstem [19,26] and indirectly increases the release of gastrointestinal hormones, including cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and other hormones such as insulin and leptin, which stimulate the release of neurotransmitters responsible for the feeling of satiety and inhibit the release of neurotransmitters responsible for the feeling of hunger in the arcuate nucleus of the hypothalamus [26,27,28,29]. Furthermore, estradiol inhibits the release of the hunger-stimulating hormone ghrelin in the stomach [30].
Studies assessing changes in energy intake during the menstrual cycle are inconclusive. Some show an increase in intake from 87 to 500 kcal during the luteal phase [31,32], while others found no significant changes [33,34,35]. Interestingly, it has been observed that estradiol levels influence women’s perceptions of food [24,36]. Lower estradiol and higher progesterone levels during the luteal phase were associated with increased reactivity to high-energy food pictures in studies performed using EEG and functional magnetic resonance [36,37,38,39]. In addition, more frequent food cravings, binge eating, and increased fat or carbohydrate intake were observed during the luteal phase [40,41,42,43,44].

3. PMS and Dietary Composition and Patterns

The relationship between PMS, dietary composition, and dietary patterns seems to be bidirectional. However, the results of studies assessing these relationships are inconclusive. A recently published study showed no association between dietary components, except for copper intake and PMS [45]. Moreover, no association between PMS and the intake of cereals, dairy products, caffeine, fat, sweets, vegetables, fruits, spices, or pickles was shown [46]. Furthermore, Houghton et al. [47] observed no correlation between fiber, carbohydrate, and protein intake and PMS [47]. While, another study found a significant premenstrual increase in fat and simple carbohydrates, as well as a decrease in protein intake in women with PMS [48]. Furthermore, a significant inverse association between PMS severity and fish and seafood consumption was observed [46]. Moreover, positive correlations were observed between consuming a high-energy diet rich in fat, sugar, and salt and with severity of physical symptoms of PMS. Fruit consumption was associated with a decreased risk of psychological symptoms of PMS [49]. In addition, a relationship between a diet rich in red and processed meat, fast food, vegetable oil, mayonnaise, deep-fried foods, salty snacks, refined grains, sugar and soft drinks, high-fat dairy products, spices, and fried potatoes and an increased risk of developing PMS symptoms, was observed [50].
It has also been suggested that women with PMS are more sensitive to hormonal fluctuations during the menstrual cycle, resulting in higher consumption of simple carbohydrates during the premenstrual period [36]. Simple carbohydrate intake may be a counterregulatory mechanism for decreased mood because it increases serotonin and dopamine release in the brain [51]. Mood swings are a common symptom of PMS. The associations between serotonin release in the brain and mood regulation were found [52]. Carbohydrates increase the availability of tryptophan, a precursor of serotonin. A sharply lowering blood glucose level may be the cause of irritability. Thus, changes in blood glucose levels can shape the relationship between carbohydrate consumption and mood fluctuations [53]. However, a recently published study has shown a similar simple carbohydrate and fiber intake in women with and without PMS [45].
It should be noted that the current studies assessing the main dietary factors provide inadequate data. Most studies have focused on the assessment of the potential effects of selected dietary components, which limits the accuracy of the conclusions. Importantly, PMS per se may affect food choices, and these choices can influence the worsening or relief of symptoms. Therefore, the data so far permits the conclusion that there is a relationship between the composition of diet and PMS but does not allow us to establish a certain cause-and-effect relationship.

3.1. Macronutrient Intake and PMS

Studies assessing the association between macronutrient intake and PMS have been inconclusive. Some studies have shown a positive association between PMS symptoms and a diet rich in simple carbohydrates, fried foods, and alcohol and a negative association between PMS symptoms and a diet rich in vegetables, fruits, and fiber [19,47,50,54,55]. Another study found no association between fiber and carbohydrate intake, except for maltose, and PMS development. The highest intake of maltose was associated with a 45% increased risk of developing PMS after adjusting for BMI, smoking, and other factors [56].
A large cohort study found no association between fat intake and PMS risk [57]. Another study showed a negative association between high stearic acid intake and PMS development [56]. Furthermore, no correlation between protein intake and PMS was found [58]. The association between micronutrient intake and PMS is shown in Table 1.
In summary, assessing the relationship between the occurrence of PMS, the severity of its symptoms, and the consumption of macronutrients is very difficult, which may result in large discrepancies in the results of published studies. These relationships may also be temporal. In diet composition analyses, it is impossible to reliably assess the long-term intake of individual macronutrients. Moreover, it should be emphasized that all the tools used to analyze diet composition have numerous limitations, including respondents’ memory and truthfulness. Therefore, based on the available data, it is difficult to formulate recommendations regarding the consumption of macronutrients to alleviate the severity of PMS symptoms.

3.2. Micronutrient Intake and PMS

Several hypotheses have been proposed regarding the effect of micronutrient deficiencies on the development of PMS.
One study suggested that PMS is a clinical manifestation of calcium deficiency. This hypothesis may be supported by changes in calcium concentration during the menstrual cycle and the relationship between calcium homeostasis and affective disorders [59]. Moreover, significantly lower calcium and magnesium levels have been observed in women with PMS. Furthermore, calcium, magnesium, and potassium intakes were lower in women with PMS than without PMS [60]. In addition, supplementation with 1200 mg of calcium carbonate daily during three menstrual cycles in women with PMDD reduced the severity of psychological and physical symptoms by 48% [61].
Another hypothesis links PMS with iron deficiency. It has been shown that a higher intake of iron, especially non-heme iron, significantly reduces the risk of development of PMS [62]. Moreover, PMS symptoms, including confusion, headaches, and nausea, are less common in women with a genetically increased risk of iron overload [63].
In addition, a randomized clinical trial (RCT) showed that supplementation with 220 mg of elemental zinc daily for 24 weeks reduced the severity of PMS symptoms and improved quality of life compared with the placebo group [64,65]. Most of these studies were conducted among Arab women. The associations between micronutrient intake and PMS are shown in Table 2.

3.3. Vitamin Intake and PMS

An inverse association was observed between thiamine and riboflavin intake and PMS. However, supplementation did not significantly reduce the severity of PMS symptoms [66].
Studies assessing the effect of vitamin B6 supplementation on PMS symptoms are inconclusive. One study showed no difference in PMS symptom severity between the group supplemented with vitamin B6 (80 mg/day) and the group supplemented with broad-spectrum micronutrient formulas during three menstrual cycles. Complete remission of PMS symptoms was observed in 72% of the group supplemented with micronutrients and 60% of the group supplemented with vitamin B6 [67]. A meta-analysis of 12 case-control studies, including 586 women with PMS supplemented with vitamin B6 and 602 receiving a placebo, found a significant improvement in both the physical and psychological symptoms of PMS in women supplemented with vitamin B6 [68].
Furthermore, some trials have shown that supplementation with 80 mg of thiamine daily for two menstrual cycles decreased the severity of PMS symptoms compared with placebo [69]. Moreover, another study found that daily supplementation with 100 mg thiamine and 500 mg calcium carbonate reduced the severity of PMS symptoms more than supplementation with 100 mg thiamine, 500 mg calcium carbonate, or placebo [70].
There are also associations between vitamin D insufficiency and the risk of developing PMS [71] and the severity of its symptoms [72]. However, vitamin D intake did not affect the risk of developing PMS [73,74]. Supplementation with 50,000 IU/week of vitamin D decreased the incidence of several symptoms of PMS, including back pain and a tendency to cry easily, as well as the severity of dysmenorrhea in adolescents [75]. Moreover, vitamin D supplementation (200,000 IU initially, followed by 25,000 IU every 2 weeks) for 4 months decreased mood symptoms related to PMS in young women with severe vitamin D insufficiency [76]. The effect of vitamin D supplementation on the reduction of the severity of PMS symptoms has also been confirmed in other studies [77,78,79], systematic reviews, and meta-analyses of 16 studies (5 interventional and 11 observational) which included 4946 women [80]. The associations between vitamin intake and PMS are shown in Table 3.

3.4. Other Nutrients and PMS

A randomized, placebo-controlled, double-blind clinical trial involving 40 women with PMS showed that supplementation with lecithin-phosphatidylserine (400 mg daily) and phosphatidic acid complex (400 mg daily) for three menstrual cycles significantly reduced the severity of both physical and psychological symptoms [81].
A meta-analysis of eight RCTs found that omega-3 fatty acids may reduce the severity of PMS, but its efficacy depends on the duration of use [82]. While few studies have explored the relationship between inflammation, oxidative stress, and PMS, existing data remains limited [83]. Furthermore, decreased estradiol levels may contribute to the development of inflammation exacerbating premenstrual symptoms such as menstrual pain, mood changes, and increased bleeding [84]. Omega-3 fatty acids have anti-inflammatory properties related to competitive interactions with arachidonic acid as a substrate for cyclooxygenases and 5-lipoxygenases. Especially eicosatetraenoic acid and docosahexaenoic acid reduce inflammation by inhibiting leukocyte chemotaxis, regulating the expression of adhesion molecules, modulating leukocyte-endothelial adhesive interactions, suppressing eicosanoid production, and inhibiting the synthesis of pro-inflammatory cytokines [85,86,87]. Thus, omega-3 fatty acids intake may alleviate PMS symptoms related to inflammation.
The association between caffeine and caffeinated drink consumption and PMS has also been assessed, but the results are inconclusive. Some studies showed a strong positive association between caffeine and caffeinated drink consumption and PMS severity [82,87,88,89,90,91]. However, other studies have not found these associations [92,93]. Moreover, the prospective Nurses’ Health Study II found that highly caffeinated coffee consumption was not associated with the risk of the development of PMS or its specific symptoms, such as breast tenderness [94].
It has also been observed that tryptophan supplements and complex carbohydrate-enriched drinks significantly decreased the severity of PMS symptoms compared to placebo [57,95].
The associations between intake of other nutrients and PMS are shown in Table 4.

4. PMS and Eating Behaviors

The relationship between eating habits and PMS is complex. In a study of 383 adolescents, PMS symptoms were found in 55.9% of participants. Disordered eating was significantly more common in the PMS group than in the non-PMS group. Moreover, emotional and uncontrolled eating scores were higher in the PMS group [96]. Another study showed a significantly higher EAT-26 score and overall prevalence of eating disorders in the group with PMDD than in the group with moderate-to-severe, mild, or no PMS symptoms [97]. It has also been suggested that physical and psychological PMS symptoms are associated with a higher risk of developing eating disorder symptoms [98,99]. In addition, among women with binge eating symptoms, the occurrence of moderate and severe physical and psychological PMS symptoms was significantly more common, while no association between binge eating disorders and either PMS or PMDD was found. However, a more than 7-fold increased odds ratio of developing bulimia nervosa was associated with PMDD, and a more than 2-fold increased odds ratio with PMS [100]. In most studies, self-reporting surveys or diaries were used, and data were analyzed retrospectively, which may introduce potential bias and discrepancies. Furthermore, some studies failed to assess co-existing psychiatric disorders and used supplements or vitamins that may influence PMS symptoms. Moreover, the menstrual cycle phases were not considered. The symptoms of eating disorders may differ between menstrual cycle phases [97]. Additionally, any type of birth control used that may influence eating behavior and PMS symptoms and the timeframe of their use were not analyzed. Considering these limitations, it is impossible to draw definitive conclusions regarding cause and effect relationship. Thus, there is a critical need for large-scale, longitudinal studies in both clinical settings and the general population to clarify the relationship between PMS and eating disorders.

5. Managing PMS

The primary goal of PMS treatment is to alleviate symptoms and minimize their impact on daily activities. PMS treatment should be individualized according to the patient’s symptom profile and should include nonpharmacological and pharmacological interventions. Non-pharmacological interventions include cognitive behavioral therapy [101] and lifestyle changes comprising nutritional therapy [102]. The current guidelines [2,4] for managing PMS do not include individualization of therapy depending on the severity of symptoms and hormonal profile except for surgical treatment. Potential treatment options for women with PMS are shown in Figure 1.

5.1. Nonpharmacological Treatment

5.1.1. Nutritional Treatment

Nutritional treatment is an important component of the non-pharmacological treatment of PMS. This involves the implementation of dietary modifications. It has also been suggested that the involvement of a multidisciplinary healthcare team, including a dietitian, can be beneficial [5]. Researchers at the Mayo Clinic emphasize the importance of not only the composition of the diet but also eating smaller and more frequent meals to alleviate PMS symptoms such as bloating and feelings of fullness [6]. Similarly, the ACOG stressed the importance of meal frequency, suggesting the consumption of six small meals instead of three larger meals. This dietary pattern may help to maintain stable blood glucose levels and potentially reduce PMS symptoms [103]. Consistent guidelines recommend a diet rich in complex carbohydrates, including fruits, vegetables, and whole grains. Such dietary choices can prevent mood fluctuations and food cravings commonly associated with PMS. Moreover, the diet should contain calcium-rich foods, such as yoghurt and leafy greens [6]. In turn, fat, sugar, and salt intake should be limited because excessive consumption promotes bloating and fluid retention [103,104]. In addition, the National Association for Premenstrual Syndrome (NAPS) recommends limiting alcohol and caffeine consumption [6,103,104].

5.1.2. Use of supplements

The Royal College of Obstetricians and Gynecologists, as first-line treatment, for PMDD recommends vitamin B6 supplementation, despite the low level of evidence for its effectiveness [102]. However, high B6 doses may promote the development of peripheral neuropathy [105]. The NAPS recommend vitamin B6 for treating mild-to-moderate PMS, with a maximum daily intake of 50 mg under the supervision of a primary care physician. However, available evidence supporting its efficacy remains insufficient. Furthermore, NAPS suggest the daily use of 1 g calcium and 10 µg vitamin D3, especially for migraine treatment. ACOG recommends supplementation of 1.2 mg calcium daily to alleviate both physical and psychological PMS symptoms, especially reducing water retention and breast tenderness [105,106]. The Mayo Clinic highlights the supplementation of calcium, magnesium, vitamin E, vitamin B6, and herbal remedies but underscores the lack of conclusive evidence supporting their effectiveness [6]. Further studies are necessary to assess the effectiveness of dietary recommendations and refine treatment protocols.
Preliminary results suggest that regular magnesium supplementation at 250 mg daily decreases the severity of PMS symptoms. In addition, some data have indicated the benefits of using isoflavones [106].
The efficacy of the fruit extract of agnus castus in reducing the severity of irritability and mood swings related to PMS has also been found [106,107]. However, no comparative studies with SSRIs and oral contraceptive pills have been conducted.
Due to the inadequacy of sufficient data and the unpredictability of the treatment’s efficacy or the substantial shortcomings in the study’s methodology, the use of supplements in the treatment of PMS should be considered as a complementary and not a primary option [3,7].

5.1.3. Cognitive Behavior Therapy

Cognitive behavioral therapy (CBT) is a therapeutic method that focuses on correcting maladaptive thoughts, behaviors, and emotions that cause distress and impair daily functioning [104]. One meta-analysis [108] of five randomized controlled trials (RCTs) of CBT in women with PMS found significant reductions in symptoms of anxiety and depression, although the quality of the trials was rated as low due to weaknesses in study design and implementation and potential reporting bias. However, the majority of evidence supports the effectiveness of CBT for both PMS and PMDD [109]. Moreover, a meta-analysis revealed that CBT is equally effective as antidepressant medications in treating PMS and PMDD, suggesting that combining therapies may result in better outcomes [110].

5.1.4. Lifestyle Modification

Lifestyle modifications include regular physical activity, avoidance of stressful situations, and maintenance of healthy sleep patterns, particularly during the premenstrual period. Knowledge about the beneficial effects of physical activity on health justifies its recommendation in the treatment of PMS [103]. However, the quality of studies showing the positive impact of physical activities including swimming [111], pilates [112] or aerobic exercise [113] on PMS symptoms is limited. Although a meta-analysis of 7 RCT has also shown benefits [114], the variability of these studies limits their reliability. In turn, in a group of 106 young women with PMS divided into three subgroups (diet, aerobic exercise, and control) it was found that both 3 months of diet or aerobic exercise reduced PMS symptoms and dysmenorrhea intensity [115].

5.2. Pharmacological Treatment

5.2.1. Selective Serotonin Reuptake Inhibitors

Although the mechanism of action remains unclear [116], the gold standard pharmacotherapy for PMDD is treatment with selective serotonin reuptake inhibitors (SSRIs), administered continuously or only during the luteal phase of the menstrual cycle [117]. It is considered that SSRIs modulate the synthesis of allopregnanolone, although their mechanism of action in this regard is unknown [117,118]. One open-label trial assessed treatment with sertraline in PMDD and demonstrated alterations in total peripheral allopregnanolone levels [118]. The beneficial effects of SSRIs have been confirmed in a meta-analysis of 19 RCTs involving 2964 women with PMS and/or PMDD, and no SSRI was superior to the others [119]. However, the side effects related to SSRI use, including sexual dysfunction, suicidal ideation, and insomnia, may reduce their beneficial effects [120,121,122].

5.2.2. Combined Oral Contraceptives

Combined oral contraceptives are an effective therapy for physical symptoms associated with the menstrual cycle, such as menorrhagia, dysmenorrhea, and gastrointestinal disturbances. However, the data assessing their effect on PMS affective symptoms are inconclusive [123]. Different combinations of hormones, doses, and use times further confound the data. The US Food and Drug Administration (FDA) approved a combination of drospirenone and ethinyl estradiol for the treatment of PMDD [124]. Combined contraceptive pills containing different gestagens and ethinyl estradiol are recommended for treating PMS and PMDD [122]. However, combined oral contraceptive pills are not effective in reducing depressive symptoms [125]. Moreover, they are contraindicated in women with an increased risk of venous thrombosis and breast cancer [126]. The potential side effects include those commonly reported (e.g., headache, metrorrhagia, menorrhagia, acne, intermenstrual vaginal bleeding, decreased libido, mood swings) [127] and those less frequent but serious (thrombotic events [128], an increase in the risk of breast cancer [129]), may be a cause of noncompliance and the decrease of effectiveness.

5.3. Surgical Treatment

Hysterectomy with bilateral salpingectomy/oophorectomy is recommended for patients aged 40 years and over, after confirming the lack of effects of conservative treatment [130]. This surgery results in premature menopause and its consequences [131]. Therefore, hormone replacement therapy is necessary to prevent increased cardiovascular risk, osteoporosis [132], depressive and anxiety symptoms and adverse effects on sexual health [133], and cognitive decline [134]. Another option is an invasive endometrial ablation procedure [135]. Nevertheless, the data assessing the effect of surgical treatment on PMS are scarce and further research is required to substantiate these preliminary findings.

5.4. Future Therapies

As was mentioned above, one hypothesis concerning the etiology of PMS is the disrupted regulation of GABA receptors. Therefore, one strategy for treating PMS and PMDD may be to regulate the action of allopregnanolone (ALLO) on GABA receptors. Initial studies assessing selective progesterone receptor modulators (SPRMs), especially mifepristone, in the treatment of the symptoms of severe PMS, did not confirm their effectiveness. However, a recent study confirmed the effectiveness of ulipristal acetate (second-generation SPRMs) in the treatment of the emotional and behavioral symptoms of PMDD. Moreover, current studies’ endeavors in the advancement of treatment methods for PMDD are primarily oriented towards achieving stabilization of ALLO signaling. Dutasteride, an inhibitor of 5-alpha-reductase, responsible for the conversion of progesterone to ALLO, is one such candidate. In addition, sepranolone, an allosteric modulator of the GABA-A receptor, is under investigation [136].

5.5. Interactions

The components of the treatment of PMS may interact in a complex manner. It has been suggested that the use of COCs may decrease the concentrations of various nutritional ingredients including riboflavin, pyridoxine, folacin, vitamin B12, ascorbic acid, and zinc, and potentially increase the levels of vitamin K, iron, and copper [137,138]. Other studies show a correlation between OC use and reduced levels of vitamin B12 and vitamin B6 [139]. A change in vitamin D levels associated with oral estrogens has also been found [140]. Thus, some data suggest that dietary management may not be effective in reducing PMS symptoms [141]. It has also been shown that high vitamin B6 intake may impair the efficacy of antidepressants [142]. While, magnesium and calcium supplements may affect the bioavailability of antibiotics, including fluoroquinolone [143]. Herbal preparations may increase menstrual bleeding, gastrointestinal symptoms [144] and excessive sleepiness [145]. Thus, simultaneous use of supplements and pharmacological therapies may increase the risk of adverse effects. Moreover, SSRIs such as paroxetine, fluoxetine, and sertraline used in PMS treatment can alter bleeding parameters, potentially exacerbating side effects, for instance, following surgical interventions [146].

5.6. Individualized Nutritional Therapy

Considering the reciprocal relationship between diet and PMS, a personalized plan is essential, involving an analysis of patient dietary patterns and macronutrients and micronutrient intake to identify shortcomings and recommend beneficial changes.
It has been suggested that the intake of foods rich in vitamin B and magnesium intensifies the duration of migraine headaches related to PMS [147]. Furthermore, increasing calcium and magnesium intake has the potential to alleviate the effect of mood swings and bloating [6]. Similarly, omega-3 fatty acids, vitamin B6, and vitamin D supplementation can reduce inflammation, stabilize mood, and regulate hormones [85]. While reducing simple carbohydrates may prevent blood glucose level fluctuations and related to exacerbation of irritability or cravings [42]. It also seems that tailoring nutritional interventions to hormonal fluctuations may improve PMS symptoms [148].
Individualized nutritional therapy requires ongoing monitoring and periodic adjustments to the changing needs of those suffering from PMS.

6. Potential Impact of PMS and PMDD on Quality of Life, Interpersonal Relationships, and Work Productivity

Numerous observational studies have shown the adverse impact of PMS on the physical and psychological domains of quality of life [149,150,151,152], its social domains [153,154,155], and interpersonal relationships [156,157]. PMS may also affect productivity and professional life during the luteal phase and the post-episode period [158]. A significant correlation between PMS severity and several factors, including reduced presenteeism, intention to reduce working hours, and increased absenteeism from work, was found. Importantly, due to feelings of embarrassment, on rare occasions, women may choose to request sick leave and disclose their PMS symptoms, primarily because of concerns about the appropriateness of taking time off work [159]. A large case-control study showed a higher prevalence of productivity-related impairments in the PMS group than in the group without PMS [160]. PMS also affects sleep quality. A systematic review and meta-analysis showed the adverse effects of PMS on various aspects of sleep, including satisfaction, alertness, efficiency, and duration [161]. In addition, some studies have found an increased risk of suicide in women with PMS and PMDD [162].
The selected studies that assessed the adverse outcomes of PMS are presented in Table 5.

7. Future Direction

Diet appears to be an important factor modulating the risk of development and severity of PMS symptoms. However, studies assessing the effects of macro- and micronutrients on the development of PMS and the severity of its symptoms are limited and are of insufficient quality. Further high-quality studies are needed to confirm the impact of diet on PMS e, in particular, double-/triple-blind placebo-controlled RCTs with a follow-up of large cohorts. In addition, confounding factors including stress, interpersonal relationships, and meal supervision should be considered. This will allow for the formulation of more effective nutritional recommendations for women with PMS.

8. Conclusions

Diet seems to be an important factor in the development of PMS and the modulation of its symptoms. A diet consisting of unprocessed, fresh foods and limiting simple carbohydrates, fats, salt, and alcohol intake may prevent the development of PMS and reduce the severity of its symptoms. However, further studies are necessary to formulate clear dietary recommendations. In addition, the benefits of individualized micronutrients and vitamin supplementation in the treatment of PMS are suggested. However, it should be emphasized that large randomized placebo-controlled trials in racially diverse populations are needed to formulate definitive and personalized recommendations regarding the supplementation of micronutrients and vitamins in women with PMS.

Author Contributions

P.O. and N.O. contributed to the manuscript concept, analyzed the literature, and drafted the manuscript, M.W. and T.B.R. analyzed the literature and drafted the manuscript, M.O.-G. critical revision, P.K. contributed to the manuscript concept and drafted the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank native speaker Mike Smertka for the linguistic revision.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Halbreich, U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder--clinical procedures and research perspectives. Gynecol. Endocrinol. 2004, 19, 320–334. [Google Scholar] [CrossRef] [PubMed]
  2. American College of Obstetricians and Gynecologists. Guidelines for Women’s Health Care: A Resource Manual, 4th ed.; American College of Obstetricians and Gynecologists: Washington, DC, USA, 2014; pp. 607–613. [Google Scholar]
  3. Connolly, M. Premenstrual syndrome: An update on definitions, diagnosis and management. Adv. Psych. Treat. 2001, 7, 469–477. [Google Scholar] [CrossRef]
  4. Available online: https://www.pms.org.uk/about-pms-2/what-is-pms/definitions-pms-pmdd (accessed on 11 May 2024).
  5. Available online: https://www.acog.org/womens-health/faqs/premenstrual-syndrome (accessed on 11 May 2024).
  6. Available online: https://www.pms.org.uk/app/uploads/2018/06/guidelinesfinal60210.pdf (accessed on 11 May 2024).
  7. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-treatment-premenstrual-dysphoric-disorder-pmdd_en.pdf (accessed on 11 May 2024).
  8. AbdelQadir, Y.H.; Assar, A.; Abdelghafar, Y.A.; Kamal, M.A.; Zaazouee, M.S.; Elsayed, S.M.; Ragab, K.M.; Nabhan, A.E.; Gamaleldin, N.A.; IMedRA Collaborators Team. Prevalence and patterns of premenstrual disorders and possible association with sexual harassment: A cross-sectional study of young Arab women. BMC Women’s Health 2022, 22, 536. [Google Scholar] [CrossRef] [PubMed]
  9. Direkvand Moghadam, A.; Kaikhavani, S.; Sayehmiri, K. The world-wide prevalence of premenstrual syndrome: A systematic re-view and meta-analysis study. Iran. J. Obstet. Gynecol. Infertil. 2013, 16, 8–17. [Google Scholar]
  10. Andualem, F.; Melkam, M.; Takelle, G.M.; Nakie, G.; Tinsae, T.; Fentahun, S.; Rtbey, G.; Seid, J.; Gedef, G.M.; Bitew, D.A.; et al. Prevalence of premenstrual syndrome and its associated factors in Africa: A systematic review and meta-analysis. Front. Psychiatry 2024, 15, 1338304. [Google Scholar] [CrossRef] [PubMed]
  11. Chumpalova, P.; Iakimova, R.; Stoimenova-Popova, M.; Aptalidis, D.; Pandova, M.; Stoyanova, M.; Fountoulakis, K.N. Prevalence and clinical picture of premenstrual syndrome in females from Bulgaria. Ann. Gen. Psychiatry 2020, 19, 3. [Google Scholar] [CrossRef] [PubMed]
  12. Rezende, A.P.R.; Alvarenga, F.R.; Ramos, M.; Franken, D.L.; Dias da Costa, J.S.; Pattussi, M.P.; Paniz, V.M.V. Prevalence of Premenstrual Syndrome and Associated Factors Among Academics of a University in Midwest Brazil. Rev. Bras. Ginecol. Obstet. 2022, 44, 133–141. [Google Scholar] [CrossRef] [PubMed]
  13. Lee, W.; Lee, S.; Ahn, J.; Lee, R.S.; Kang, S.K. Premenstrual syndrome incidence rate and risk factors among the working population in the Republic of Korea: A prospective cohort study. BMC Women’s Health 2022, 22, 265. [Google Scholar] [CrossRef] [PubMed]
  14. Turan, A.; Güler Kaya, İ.; Çakır, H.B.; Topaloğlu, S. Prevalence and correlates of premenstrual syndrome and premenstrual dysphoric disorder among women aged 18–25 in Turkey. Int. J. Psychiatry Med. 2024, 59, 101–111. [Google Scholar] [CrossRef]
  15. Hantsoo, L.; Epperson, C.N. Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Curr. Psychiatry. Rep. 2015, 17, 87. [Google Scholar] [CrossRef]
  16. Gao, M.; Gao, D.; Sun, H.; Cheng, X.; An, L.; Qiao, M. Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder From 1945 to 2018: A Bibliometric Analysis. Front. Public Health 2021, 9, 596128. [Google Scholar] [CrossRef]
  17. Siminiuc, R.; ŇĘurcanu, D. Impact of nutritional diet therapy on premenstrual syndrome. Front. Nutr. 2023, 10, 1079417. [Google Scholar] [CrossRef]
  18. Bertone-Johnson, E.R.; Hankinson, S.E.; Willett, W.C.; Johnson, S.R.; Manson, J.E. Adiposity and the development of premenstrual syndrome. J. Women’s Health 2010, 19, 1955–1962. [Google Scholar] [CrossRef]
  19. Asarian, L.; Geary, N. Estradiol enhances cholecystokinin-dependent lipid-induced satiation and activates estrogen receptor-alpha-expressing cells in the nucleus tractus solitarius of ovariectomized rats. Endocrinology 2007, 148, 5656–5666. [Google Scholar] [CrossRef]
  20. Gudipally, P.R.; Sharma, G.K. Premenstrual Syndrome. In StatPearls [Internet]; StatPearls: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK560698/# (accessed on 11 May 2024).
  21. Gorczyca, A.M.; Sjaarda, L.A.; Mitchell, E.M.; Perkins, N.J.; Schliep, K.C.; Wactawski-Wende, J.; Mumford, S.L. Changes in macronutrient, micronutrient, and food group intakes throughout the menstrual cycle in healthy, premenopausal women. Eur. J. Nutr. 2016, 55, 1181–1188. [Google Scholar] [CrossRef]
  22. Elliott, S.A.; Ng, J.; Leow, M.; Henry, C.J. The influence of the menstrual cycle on energy balance and taste preference in Asian Chinese women. Eur. J. Nutr. 2015, 54, 1323–1332. [Google Scholar] [CrossRef]
  23. Leeners, B.; Geary, N.; Tobler, P.N.; Asarian, L. Ovarian hormones and obesity. Hum. Reprod. Update 2017, 23, 300–321. [Google Scholar] [CrossRef]
  24. Hirschberg, A.L. Sex hormones, appetite and eating behaviour in women. Maturitas 2012, 71, 248–256. [Google Scholar] [CrossRef]
  25. Asarian, L.; Abegg, K.; Geary, N.; Schiesser, M.; Lutz, T.A.; Bueter, M. Estradiol increases body weight loss and gut-peptide satiation after Roux-en-Y gastric bypass in ovariectomized rats. Gastroenterology 2012, 143, 325–327. [Google Scholar] [CrossRef]
  26. Asarian, L.; Geary, N. Sex differences in the physiology of eating. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305, R1215–R1267. [Google Scholar] [CrossRef]
  27. Crespo, C.J.; Smit, E.; Snelling, A.; Sempos, C.T.; Andersen, R.E. Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002, 25, 1675–1680. [Google Scholar] [CrossRef]
  28. Fungfuang, W.; Nakada, T.; Nakao, N.; Terada, M.; Yokosuka, M.; Gizurarson, S.; Hau, J.; Moon, C.; Saito, T.R. Serum leptin concentrations, leptin mRNA expression, and food intake during the estrous cycle in rats. Lab. Anim. Res. 2013, 29, 1–6. [Google Scholar] [CrossRef]
  29. Frank, A.; Brown, L.M.; Clegg, D.J. The role of hypothalamic estrogen receptors in metabolic regulation. Front. Neuroendocrinol. 2014, 35, 550–557. [Google Scholar] [CrossRef]
  30. Lissner, L.; Stevens, J.; Levitsky, D.A.; Rasmussen, K.M.; Strupp, B.J. Variation in energy intake during the menstrual cycle: Implications for food-intake research. Am. J. Clin. Nutr. 1988, 48, 956–962. [Google Scholar] [CrossRef]
  31. Dalvit, S.P. The effect of the menstrual cycle on patterns of food intake. Am. J. Clin. Nutr. 1981, 34, 1811–1815. [Google Scholar] [CrossRef]
  32. Lundman, B.; Asplund, K.; Norberg, A. Metabolic control, food intake and mood during the menstrual cycle in patients with insulin-dependent diabetes. Int. J. Nurs. Stud. 1994, 31, 391–401. [Google Scholar] [CrossRef]
  33. Piers, L.S.; Diggavi, S.N.; Rijskamp, J.; van Raaij, J.M.; Shetty, P.S.; Hautvast, J.G. Resting metabolic rate and thermic effect of a meal in the follicular and luteal phases of the menstrual cycle in well-nourished Indian women. Am. J. Clin. Nutr. 1995, 61, 296–302. [Google Scholar] [CrossRef]
  34. Bryant, M.; Truesdale, K.P.; Dye, L. Modest changes in dietary intake across the menstrual cycle: Implications for food intake research. Br. J. Nutr. 2006, 96, 888–894. [Google Scholar] [CrossRef]
  35. Derntl, B.; Sch√∂pf, V.; Kollndorfer, K.; Lanzenberger, R. Menstrual cycle phase and duration of oral contraception intake affect olfactory perception. Chem. Senses 2013, 38, 67–75. [Google Scholar] [CrossRef]
  36. Strahler, J.; Hermann, A.; Schmidt, N.M.; Stark, R.; Hennig, J.; Munk, A.J. Food cue-elicited brain potentials change throughout menstrual cycle: Modulation by eating styles, negative affect, and premenstrual complaints. Horm. Behav. 2020, 124, 104811. [Google Scholar] [CrossRef]
  37. Frank, T.C.; Kim, G.L.; Krzemien, A.; Van Vugt, D.A. Effect of menstrual cycle phase on corticolimbic brain activation by visual food cues. Brain Res. 2010, 1363, 81–92. [Google Scholar] [CrossRef]
  38. Pletzer, B.; Crone, J.S.; Kronbichler, M.; Kerschbaum, H. Menstrual Cycle and Hormonal Contraceptive-Dependent Changes in Intrinsic Connectivity of Resting-State Brain Networks Correspond to Behavioral Changes Due to Hormonal Status. Brain Connect 2016, 6, 572–585. [Google Scholar] [CrossRef]
  39. Cohen, I.T.; Sherwin, B.B.; Fleming, A.S. Food cravings, mood, and the menstrual cycle. Horm. Behav. 1987, 21, 457–470. [Google Scholar] [CrossRef]
  40. Bowen, D.J.; Grunberg, N.E. Variations in food preference and consumption across the menstrual cycle. Physiol. Behav. 1990, 47, 287–291. [Google Scholar] [CrossRef]
  41. Hill, A.J.; Heaton-Brown, L. The experience of food craving: A prospective investigation in healthy women. J. Psychosom. Res. 1994, 38, 801–814. [Google Scholar] [CrossRef]
  42. Brzezinski, A.A.; Wurtman, J.J.; Wurtman, R.J.; Gleason, R.; Greenfield, J.; Nader, T. d-Fenfluramine suppresses the increased and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet. Gynecol. 1990, 76, 296–301. [Google Scholar] [CrossRef]
  43. Rogan, M.M.; Black, K.E. Dietary energy intake across the menstrual cycle: A narrative review. Nutr. Rev. 2023, 81, 869–886. [Google Scholar] [CrossRef]
  44. Quaglia, C.; Nettore, I.C.; Palatucci, G.; Franchini, F.; Ungaro, P.; Colao, A.; Macchia, P.E. Association between Dietary Habits and Severity of Symptoms in Premenstrual Syndrome. Int. J. Environ. Res. Public Health 2023, 20, 1717. [Google Scholar] [CrossRef]
  45. Helmy, N.A.; Kamel, D.M.; Gabr, A.A.; Shehata, M.M.A. Do dietary habits affect the premenstrual syndrome severity among a cohort of Egyptian females? A cross-sectional study. Bull. Fac. Phys. Ther. 2023, 28, 11. [Google Scholar] [CrossRef]
  46. Cross, G.B.; Marley, J.; Miles, H.; Willson, K. Changes in nutrient intake during the menstrual cycle of overweight women with premenstrual syndrome. Br. J. Nutr. 2001, 85, 475–482. [Google Scholar] [CrossRef]
  47. Houghton, S.C.; Manson, J.E.; Whitcomb, B.W.; Hankinson, S.E.; Troy, L.M.; Bigelow, C.; Bertone-Johnson, E.R. Carbohydrate and fiber intake and the risk of premenstrual syndrome. Eur. J. Clin. Nutr. 2018, 72, 861–870. [Google Scholar] [CrossRef]
  48. Hashim, M.S.; Obaideen, A.A.; Jahrami, H.A.; Radwan, H.; Hamad, H.J.; Owais, A.A.; Alardah, L.G.; Qiblawi, S.; Al-Yateem, N.; Faris, M.A.E. Premenstrual Syndrome Is Associated with Dietary and Lifestyle Behaviors among University Students: A Cross-Sectional Study from Sharjah, UAE. Nutrients 2019, 11, 1939. [Google Scholar] [CrossRef]
  49. Farasati, N.; Siassi, F.; Koohdani, F.; Qorbani, M.; Abashzadeh, K.; Sotoudeh, G. Western dietary pattern is related to premenstrual syndrome: A case-control study. Br. J. Nutr. 2015, 114, 2016–2021. [Google Scholar] [CrossRef]
  50. Freeman, E.W.; Stout, A.L.; Endicott, J.; Spiers, P. Treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int. J. Gynaecol. Obstet. 2002, 77, 253–254. [Google Scholar] [CrossRef]
  51. Thakur, H.; Pareek, P.; Sayyad, M.G.; Otiv, S. Association of Premenstrual Syndrome with Adiposity and Nutrient Intake Among Young Indian Women. Int. J. Women’s Health 2022, 14, 665–675. [Google Scholar] [CrossRef]
  52. Wurtman, R.J.; Wurtman, J.J. Brain serotonin, carbohydrate-craving, obesity and depression. Obes. Res. 1995, 3 (Suppl. 4), 477S–480S. [Google Scholar] [CrossRef]
  53. Benton, D. Carbohydrate ingestion, blood glucose and mood. Neurosci. Biobehav. Rev. 2002, 26, 293–308. [Google Scholar] [CrossRef]
  54. Taheri, R.; ZareMehrjardi, F.; Heidarzadeh-Esfahani, N.; Hughes, J.A.; Reid, R.E.R.; Borghei, M.; Ardekani, F.M.; Shahraki, H.R. Dietary intake of micronutrients are predictor of premenstrual syndrome, a machine learning method. Clin. Nutr. ESPEN 2023, 55, 136–143. [Google Scholar] [CrossRef]
  55. MoradiFili, B.; Ghiasvand, R.; Pourmasoumi, M.; Feizi, A.; Shahdadian, F.; Shahshahan, Z. Dietary patterns are associated with premenstrual syndrome: Evidence from a case-control study. Public Health Nutr. 2020, 23, 833–842. [Google Scholar] [CrossRef]
  56. Houghton, S.C.; Manson, J.E.; Whitcomb, B.W.; Hankinson, S.E.; Troy, L.M.; Bigelow, C.; Bertone-Johnson, E.R. Intake of dietary fat and fat subtypes and risk of premenstrual syndrome in the Nurses’ Health Study II. Br. J. Nutr. 2017, 118, 849–857. [Google Scholar] [CrossRef]
  57. Houghton, S.C.; Manson, J.E.; Whitcomb, B.W.; Hankinson, S.E.; Troy, L.M.; Bigelow, C.; Bertone-Johnson, E.R. Protein intake and the risk of premenstrual syndrome. Public Health Nutr. 2019, 22, 1762–1769. [Google Scholar] [CrossRef]
  58. Thys-Jacobs, S. Micronutrients and the premenstrual syndrome: The case for calcium. J. Am. Coll. Nutr. 2000, 19, 220–227. [Google Scholar] [CrossRef]
  59. Saeedian Kia, A.; Amani, R.; Cheraghian, B. The Association between the Risk of Premenstrual Syndrome and Vitamin D, Calcium, and Magnesium Status among University Students: A Case Control Study. Health Promot. Perspect. 2015, 5, 225–230, Erratum in Health Promot Perspect. 2016, 6, 54. [Google Scholar] [CrossRef]
  60. Thys-Jacobs, S.; Starkey, P.; Bernstein, D.; Tian, J.; Premenstrual Syndrome Study Group. Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms. Am. J. Obstet. Gynecol. 1998, 179, 444–452. [Google Scholar] [CrossRef]
  61. Chocano-Bedoya, P.O.; Manson, J.E.; Hankinson, S.E.; Johnson, S.R.; Chasan-Taber, L.; Ronnenberg, A.G.; Bigelow, C.; Bertone-Johnson, E.R. Intake of selected minerals and risk of premenstrual syndrome. Am. J. Epidemiol. 2013, 177, 1118–1127. [Google Scholar] [CrossRef]
  62. Zeitoun, T.; Dehghan Noudeh, N.; Garcia-Bailo, B.; El-Sohemy, A. Genetics of Iron Metabolism and Premenstrual Symptoms: A Mendelian Randomization Study. J. Nutr. 2021, 151, 1747–1754. [Google Scholar] [CrossRef]
  63. Ahmadi, M.; Khansary, S.; Parsapour, H.; Alizamir, A.; Pirdehghan, A. The Effect of Zinc Supplementation on the Improvement of Premenstrual Symptoms in Female University Students: A Randomized Clinical Trial Study. Biol. Trace Elem. Res. 2023, 201, 559–566. [Google Scholar] [CrossRef]
  64. Jafari, F.; Amani, R.; Tarrahi, M.J. Effect of Zinc Supplementation on Physical and Psychological Symptoms, Biomarkers of Inflammation, Oxidative Stress, and Brain-Derived Neurotrophic Factor in Young Women with Premenstrual Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Biol. Trace Elem. Res. 2020, 194, 89–95. [Google Scholar] [CrossRef]
  65. Chocano-Bedoya, P.O.; Manson, J.E.; Hankinson, S.E.; Willett, W.C.; Johnson, S.R.; Chasan-Taber, L.; Ronnenberg, A.G.; Bigelow, C.; Bertone-Johnson, E.R. Dietary B vitamin intake and incident premenstrual syndrome. Am. J. Clin. Nutr. 2011, 93, 1080–1086. [Google Scholar] [CrossRef]
  66. Retallick-Brown, H.; Blampied, N.; Rucklidge, J.J. A Pilot Randomized Treatment-Controlled Trial Comparing Vitamin B6 with Broad-Spectrum Micronutrients for Premenstrual Syndrome. J. Altern. Complement. Med. 2020, 26, 88–97. [Google Scholar] [CrossRef]
  67. Soheila, S.; Faezeh, K.; Kourosh, S.; Fatemeh, S.; Nasrollah, N.; Mahin, G.; Majid, A.S.; Mahmoud, B. Effects of vitamin B6 on premenstrual syndrome: A systematic review and meta-analysis. J. Chem. Pharm. Sci. 2016, 9, 1346–1353. [Google Scholar]
  68. Abdollahifard, S.; Rahmanian Koshkaki, A.; Moazamiyanfar, R. The effects of vitamin B1 on ameliorating the premenstrual syndrome symptoms. Glob. J. Health Sci. 2014, 6, 144–153. [Google Scholar] [CrossRef]
  69. Samieipour, S.; Tavassoli, E.; Heydarabadi, A.; Daniali, S.; Alidosti, M.; Kiani, F.; Pakseresht, M. Effect of calcium and vitamin B1 on the severity of premenstrual syndrome: A randomized control trial. Int. J. Pharm. Technol. 2016, 8, 18706–18717. [Google Scholar]
  70. Bertone-Johnson, E.R.; Hankinson, S.E.; Bendich, A.; Johnson, S.R.; Willett, W.C.; Manson, J.E. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch. Intern. Med. 2005, 165, 1246–1252. [Google Scholar] [CrossRef]
  71. Abdi, F.; Ozgoli, G.; Rahnemaie, F.S. A systematic review of the role of vitamin D and calcium in premenstrual syndrome. Obstet. Gynecol. Sci. 2019, 62, 73–86. [Google Scholar] [CrossRef]
  72. Bertone-Johnson, E.R.; Chocano-Bedoya, P.O.; Zagarins, S.E.; Micka, A.E.; Ronnenberg, A.G. Dietary vitamin D intake, 25-hydroxyvitamin D3 levels and premenstrual syndrome in a college-aged population. J. Steroid. Biochem. Mol. Biol. 2010, 121, 434–437. [Google Scholar] [CrossRef]
  73. Rajaei, S.; Akbari Sene, A.; Norouzi, S.; Berangi, Y.; Arabian, S.; Lak, P.; Dabbagh, A. The relationship between serum vitamin D level and premenstrual syndrome in Iranian women. Int. J. Reprod. Biomed. 2016, 14, 665–668. [Google Scholar] [CrossRef]
  74. Bahrami, A.; Avan, A.; Sadeghnia, H.R.; Esmaeili, H.; Tayefi, M.; Ghasemi, F.; Nejati Salehkhani, F.; Arabpour-Dahoue, M.; Rastgar-Moghadam, A.; Ferns, G.A.; et al. High dose vitamin D supplementation can improve menstrual problems, dysmenorrhea, and premenstrual syndrome in adolescents. Gynecol. Endocrinol. 2018, 34, 659–663. [Google Scholar] [CrossRef]
  75. Tartagni, M.; Cicinelli, M.V.; Tartagni, M.V.; Alrasheed, H.; Matteo, M.; Baldini, D.; De Salvia, M.; Loverro, G.; Montagnani, M. Vitamin D Supplementation for Premenstrual Syndrome-Related Mood Disorders in Adolescents with Severe Hypovitaminosis D. J. Pediatr. Adolesc. Gynecol. 2016, 29, 357–361. [Google Scholar] [CrossRef]
  76. Karimi, Z.; Dehkordi, M.A.; Alipour, A.; Mohtashami, T. Treatment of premenstrual syndrome: Appraising the effectiveness of cognitive behavioral therapy in addition to calcium supplement plus vitamin D. Psych. J. 2018, 7, 41–50. [Google Scholar] [CrossRef]
  77. Khajehei, M.; Abdali, K.; Parsanezhad, M.E.; Tabatabaee, H.R. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int. J. Gynaecol. Obstet. 2009, 105, 158–161. [Google Scholar] [CrossRef]
  78. Dadkhah, H.; Ebrahimi, E.; Fathizadeh, N. Evaluating the effects of vitamin D and vitamin E supplement on premenstrual syndrome: A randomized, double-blind, controlled trial. Iran. J. Nurs. Midwifery Res. 2016, 21, 159–164. [Google Scholar]
  79. Arab, A.; Golpour-Hamedani, S.; Rafie, N. The Association Between Vitamin D and Premenstrual Syndrome: A Systematic Review and Meta-Analysis of Current Literature. J. Am. Coll. Nutr. 2019, 38, 648–656. [Google Scholar] [CrossRef]
  80. Schmidt, K.; Weber, N.; Steiner, M.; Meyer, N.; Dubberke, A.; Rutenberg, D.; Hellhammer, J. A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial. Clin. Nutr. ESPEN 2018, 24, 22–30. [Google Scholar] [CrossRef]
  81. Mohammadi, M.M.; Dehghan Nayeri, N.; Mashhadi, M.; Varaei, S. Effect of omega-3 fatty acids on premenstrual syndrome: A systematic review and meta-analysis. J. Obstet. Gynaecol. Res. 2022, 48, 1293–1305. [Google Scholar] [CrossRef]
  82. Rossignol, A.M. Caffeine-containing beverages and premenstrual syndrome in young women. Am. J. Public Health 1985, 75, 1335–1337. [Google Scholar] [CrossRef]
  83. Granda, D.; Szmidt, M.K.; Kaluza, J. Is Premenstrual Syndrome Associated with Inflammation, Oxidative Stress and Antioxidant Status? A Systematic Review of Case-Control and Cross-Sectional Studies. Antioxidants 2021, 10, 604. [Google Scholar] [CrossRef]
  84. Graziottin, A.; Zanello, P.P. Mestruazione, inflammazione e comorbilità: Implicazioni per la salute della donna [Menstruation, inflammation and comorbidities: Implications for woman health]. Minerva Ginecol. 2015, 67, 21–34. [Google Scholar]
  85. Simopoulos, A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21, 495–505. [Google Scholar] [CrossRef]
  86. Calder, P.C. Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem. Soc. Trans. 2017, 45, 1105–1115. [Google Scholar] [CrossRef]
  87. Rossignol, A.M.; Bonnlander, H. Caffeine-containing beverages, total fluid consumption, and premenstrual syndrome. Am. J. Public Health 1990, 80, 1106–1110. [Google Scholar] [CrossRef]
  88. Rossignol, A.M.; Bonnlander, H.; Song, L.; Phillis, J.W. Do women with premenstrual symptoms self-medicate with caffeine? Epidemiology 1991, 2, 403–408. [Google Scholar] [CrossRef]
  89. Rasheed, P.; Al-Sowielem, L.S. Prevalence and predictors of premenstrual syndrome among college-aged women in Saudi Arabia. Ann. Saudi Med. 2003, 23, 381–387. [Google Scholar] [CrossRef]
  90. Pinar, G.; Colak, M.; Oksuz, E. Premenstrual Syndrome in Turkish college students and its effects on life quality. Sex. Reprod. Healthc. 2011, 2, 21–27. [Google Scholar] [CrossRef]
  91. Gold, E.B.; Bair, Y.; Block, G.; Greendale, G.A.; Harlow, S.D.; Johnson, S.; Kravitz, H.M.; Rasor, M.O.; Siddiqui, A.; Sternfeld, B.; et al. Diet and lifestyle factors associated with premenstrual symptoms in a racially diverse community sample: Study of Women’s Health Across the Nation (SWAN). J. Women’s Health 2007, 16, 641–656. [Google Scholar] [CrossRef]
  92. Caan, B.; Duncan, D.; Hiatt, R.; Lewis, J.; Chapman, J.; Armstrong, M.A. Association between alcoholic and caffeinated beverages and premenstrual syndrome. J. Reprod. Med. 1993, 38, 630–636. [Google Scholar]
  93. Purdue-Smithe, A.C.; Manson, J.E.; Hankinson, S.E.; Bertone-Johnson, E.R. A prospective study of caffeine and coffee intake and premenstrual syndrome. Am. J. Clin. Nutr. 2016, 104, 499–507. [Google Scholar] [CrossRef]
  94. Sayegh, R.; Schiff, I.; Wurtman, J.; Spiers, P.; McDermott, J.; Wurtman, R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet. Gynecol. 1995, 86, 520–528. [Google Scholar] [CrossRef]
  95. Isgin-Atici, K.; Buyuktuncer, Z.; Akgül, S.; Kanbur, N. Adolescents with premenstrual syndrome: Not only what you eat but also how you eat matters! J. Pediatr. Endocrinol. Metab. 2018, 31, 1231–1239. [Google Scholar] [CrossRef]
  96. Çoban, Ö.G.; Karakaya, D.; Önder, A.; İşleyen, Z.; Adanır, A.S. Association of Premenstrual Dysphoric Disorder and Eating Behaviors Among Nursing Students: A Cross-Sectional Study. J. Pediatr. Adolesc. Gynecol. 2021, 34, 203–208. [Google Scholar] [CrossRef]
  97. Hardin, S.L.; Thornton, L.M.; Munn-Chernoff, M.A.; Baker, J.H. Premenstrual symptoms as a marker of ovarian hormone sensitivity in eating disorders. Int. J. Eat Disord. 2020, 53, 296–301. [Google Scholar] [CrossRef] [PubMed]
  98. Badrasawi, M.M.; Zidan, S.J.; Natour, N.; Sharif, I.; Atrash, S.; Abueid, G.; Al-Jounde, S. Binge eating symptoms are associated with the severity of premenstrual symptoms among university students, cross sectional study from Palestine. J. Eat Disord. 2021, 9, 68. [Google Scholar] [CrossRef] [PubMed]
  99. Nobles, C.J.; Thomas, J.J.; Valentine, S.E.; Gerber, M.W.; Vaewsorn, A.S.; Marques, L. Association of premenstrual syndrome and premenstrual dysphoric disorder with bulimia nervosa and binge-eating disorder in a nationally representative epidemiological sample. Int. J. Eat Disord. 2016, 49, 641–650. [Google Scholar] [CrossRef] [PubMed]
  100. Graham, C.A.; Ramos, R.; Bancroft, J.; Maglaya, C.; Farley, T.M. The effects of steroidal contraceptives on the well-being and sexuality of women: A double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995, 52, 363–369. [Google Scholar] [CrossRef] [PubMed]
  101. Prior, J.C.; Vigna, Y.; Sciarretta, D.; Alojado, N.; Schulzer, M. Conditioning exercise decreases premenstrual symptoms: A prospective, controlled 6-month trial. Fertil. Steril. 1987, 47, 402–408. [Google Scholar] [CrossRef] [PubMed]
  102. Management of Premenstrual Syndrome: Green-top Guideline No. 48. BJOG 2017, 124, e73–e105.
  103. Kaunitz, A. New Guidance from ACOG for Treatment of Women with Menopausal Symptoms. N. Engl. J. Med. 2014. Available online: https://www.jwatch.org/na33279/2014/01/13/new-guidance-acog-treatment-women-with-menopausal-symptoms (accessed on 11 May 2024).
  104. Verkaik, S.; Kamperman, A.M.; van Westrhenen, R.; Schulte, P.F.J. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017, 217, 150–166. [Google Scholar] [CrossRef] [PubMed]
  105. Lustyk, M.K.B.; Gerrish, W.G.; Shaver, S.; Keys, S.L. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: A systematic review. Arch. Women’s Ment. Health 2009, 12, 85–96. [Google Scholar] [CrossRef]
  106. Csupor, D.; Lantos, T.; Hegyi, P.; Benkő, R.; Viola, R.; Gyöngyi, Z.; Csécsei, P.; Tóth, B.; Vasas, A.; Márta, K.; et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials. Complement. Ther. Med. 2019, 47, 102190. [Google Scholar] [CrossRef]
  107. Nevatte, T.; O’Brien, P.M.; Bäckström, T.; Brown, C.; Dennerstein, L.; Endicott, J.; Epperson, C.N.; Eriksson, E.; Freeman, E.W.; Halbreich, U.; et al. ISPMD consensus on the management of premenstrual disorders. Arch. Women’s Ment. Health 2013, 16, 279–291. [Google Scholar] [CrossRef] [PubMed]
  108. Busse, J.W.; Montori, V.M.; Krasnik, C.; Patelis-Siotis, I.; Guyatt, G.H. Psychological intervention for premenstrual syndrome: A meta-analysis of randomized controlled trials. Psychother. Psychosom. 2009, 78, 6–15. [Google Scholar] [CrossRef] [PubMed]
  109. Kancheva Landolt, N.; Ivanov, K. Short report: Cognitive behavioral therapy—A primary mode for premenstrual syndrome management: Systematic literature review. Psychol. Health Med. 2021, 26, 1282–1293. [Google Scholar] [CrossRef] [PubMed]
  110. Carlini, S.V.; Lanza di Scalea, T.; McNally, S.T.; Lester, J.; Deligiannidis, K.M. Management of Premenstrual Dysphoric Disorder: A Scoping Review. Int. J. Women’s Health 2022, 14, 1783–1801. [Google Scholar] [CrossRef] [PubMed]
  111. Maged, A.M.; Abbassy, A.H.; Sakr, H.R.S.; Elsawah, H.; Wagih, H.; Ogila, A.I.; Kotb, A. Effect of swimming exercise on premenstrual syndrome. Arch. Gynecol. Obstet. 2018, 297, 951–959. [Google Scholar] [CrossRef] [PubMed]
  112. Çitil, E.T.; Kaya, N. Effect of pilates exercises on premenstrual syndrome symptoms: A quasi-experimental study. Complement. Ther. Med. 2021, 57, 102623. [Google Scholar] [CrossRef] [PubMed]
  113. Mohebbi Dehnavi, Z.; Jafarnejad, F.; Sadeghi Goghary, S. The effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: A clinical trial study. BMC Women’s Health 2018, 18, 80. [Google Scholar] [CrossRef] [PubMed]
  114. Pearce, E.; Jolly, K.; Jones, L.L.; Matthewman, G.; Zanganeh, M.; Daley, A. Exercise for premenstrual syndrome: A systematic review and meta-analysis of randomised controlled trials. BJGP Open 2020, 4, bjgpopen20X101032. [Google Scholar] [CrossRef] [PubMed]
  115. Yilmaz-Akyuz, E.; Aydin-Kartal, Y. The effect of diet and aerobic exercise on premenstrual syndrome: Randomized controlled trial. Rev. Nutr. 2019, 32, e180246. [Google Scholar] [CrossRef]
  116. Pinna, G.; Costa, E.; Guidotti, A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr. Opin. Pharmacol. 2009, 9, 24–30. [Google Scholar] [CrossRef]
  117. Shah, N.R.; Jones, J.B.; Aperi, J.; Shemtov, R.; Karne, A.; Borenstein, J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis. Obstet. Gynecol. 2008, 111, 1175–1182. [Google Scholar] [CrossRef]
  118. Gracia, C.R.; Freeman, E.W.; Sammel, M.D.; Lin, H.; Sheng, L.; Frye, C. Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J. Clin. Psychopharmacol. 2009, 29, 403–405. [Google Scholar] [CrossRef] [PubMed]
  119. Reilly, T.J.; Wallman, P.; Clark, I.; Knox, C.L.; Craig, M.C.; Taylor, D. Intermittent selective serotonin reuptake inhibitors for premenstrual, syndromes: A systematic review and meta-analysis of randomised trials. J. Psychopharmacol. 2023, 37, 261–267. [Google Scholar] [CrossRef] [PubMed]
  120. Dimmock, P.W.; Wyatt, K.M.; Jones, P.W.; O’Brien, P.M. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review. Lancet 2000, 356, 1131–1136. [Google Scholar] [CrossRef] [PubMed]
  121. Edinoff, A.N.; Akuly, H.A.; Hanna, T.A.; Ochoa, C.O.; Patti, S.J.; Ghaffar, Y.A.; Kaye, A.D.; Viswanath, O.; Urits, I.; Boyer, A.G.; et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol. Int. 2021, 13, 387–401. [Google Scholar] [CrossRef]
  122. Yonkers, K.A.; Brown, C.; Pearlstein, T.B.; Foegh, M.; Sampson-Landers, C.; Rapkin, A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 2005, 10, 492–501. [Google Scholar] [CrossRef]
  123. Lete, I.; Lapuente, O. Contraceptive options for women with premenstrual dysphoric disorder: Current insights and a narrative review. Open Access J. Contracept. 2016, 7, 117–125. [Google Scholar] [CrossRef]
  124. Freeman, E.W.; Halbreich, U.; Grubb, G.S.; Rapkin, A.J.; Skouby, S.O.; Smith, L.; Mirkin, S.; Constantine, G.D. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 2012, 85, 437–445. [Google Scholar] [CrossRef]
  125. Grossman, D. Over-the-Counter Access to Oral Contraceptives. Obstet. Gynecol. Clin. N. Am. 2015, 42, 619–629. [Google Scholar] [CrossRef]
  126. Cronje, W.H.; Vashisht, A.; Studd, J.W. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum. Reprod. 2004, 19, 2152–2155. [Google Scholar] [CrossRef]
  127. Lee, A.; Syed, Y.Y. Estetrol/Drospirenone: A Review in Oral Contraception. Drugs 2022, 82, 1117–1125, Erratum in Drugs 2022, 82, 1341. [Google Scholar] [CrossRef] [PubMed]
  128. ESHRE Capri Workshop Group. Venous thromboembolism in women: A specific reproductive health risk. Hum. Reprod. Update 2013, 19, 471–482. [Google Scholar] [CrossRef] [PubMed]
  129. Kahlenborn, C.; Modugno, F.; Potter, D.M.; Severs, W.B. Oral contraceptive use as a risk factor for premenopausal breast cancer: A meta-analysis. Mayo Clin. Proc. 2006, 81, 1290–1302. [Google Scholar] [CrossRef] [PubMed]
  130. Reid, R.L. When should surgical treatment be considered for premenstrual dysphoric disorder? Menopause Int. 2012, 18, 77–81. [Google Scholar] [CrossRef] [PubMed]
  131. Faubion, S.S.; Kuhle, C.L.; Shuster, L.T.; Rocca, W.A. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015, 18, 483–491. [Google Scholar] [CrossRef] [PubMed]
  132. Sarrel, P.M.; Sullivan, S.D.; Nelson, L.M. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil. Steril. 2016, 106, 1580–1587. [Google Scholar] [CrossRef]
  133. Rocca, W.A.; Grossardt, B.R.; Geda, Y.E.; Gostout, B.S.; Bower, J.H.; Maraganore, D.M.; de Andrade, M.; Melton, L.J., 3rd. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008, 15, 1050–1059. [Google Scholar] [CrossRef]
  134. Bove, R.; Secor, E.; Chibnik, L.B.; Barnes, L.L.; Schneider, J.A.; Bennett, D.A.; De Jager, P.L. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014, 82, 222–229. [Google Scholar] [CrossRef]
  135. Lukes, A.S.; McBride, R.J.; Herring, A.H.; Fried, M.; Sherwani, A.; Dell, D. Improved premenstrual syndrome symptoms after NovaSure endometrial ablation. J. Minim. Invasive Gynecol. 2011, 18, 607–611. [Google Scholar] [CrossRef]
  136. Tiranini, L.; Nappi, R.E. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Fac. Rev. 2022, 11, 11. [Google Scholar] [CrossRef]
  137. Webb, J.L. Nutritional effects of oral contraceptive use: A review. J. Reprod. Med. 1980, 25, 150–156. [Google Scholar] [PubMed]
  138. Green, T.J.; Houghton, L.A.; Donovan, U.; Gibson, R.S.; O’Connor, D.L. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J. Am. Diet. Assoc. 1998, 98, 49–55. [Google Scholar] [CrossRef] [PubMed]
  139. Wilson, S.M.; Bivins, B.N.; Russell, K.A.; Bailey, L.B. Oral contraceptive use: Impact on folate, vitamin B6, and vitamin B12 status. Nutr. Rev. 2011, 69, 572–583. [Google Scholar] [CrossRef] [PubMed]
  140. Wyon, M.; Wolman, R.; Nevill, A.; Barber, A.; Edwards, M.; Bowd, B.; Clarke, F.; Bryant, J.; Cloak, R. The Influence of Hormonal Contraception on Vitamin D Supplementation on Serum 25(OH)D3 Status in Premenopausal Women: A Prospective Double-Blind Placebo Random Controlled Trial. J. Endocrinol. Metab. 2017, 7, 117–121. [Google Scholar] [CrossRef]
  141. Al Kiyumi, M.H.; Al Belushi, Z.; Al Amri, A.; Al Musharrafi, R.; Al Rashdi, F.; Jaju, S.; Al Shidhani, A.; Al Mahrezi, A. Effects of a Healthy Diet on Reducing Symptoms of Premenstrual Syndrome and Improving Quality of Life among Omani Adolescents: A Randomized Controlled Open-Label Trial. Int. J. Environ. Res. Public Health 2023, 20, 7169. [Google Scholar] [CrossRef] [PubMed]
  142. Mesripour, A.; Hajhashemi, V.; Kuchak, A. Effect of concomitant administration of three different antidepressants with vitamin B6 on depression and obsessive compulsive disorder in mice models. Res. Pharm. Sci. 2017, 12, 46–52. [Google Scholar] [CrossRef] [PubMed]
  143. Walden, D.M.; Khotimchenko, M.; Hou, H.; Chakravarty, K.; Varshney, J. Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study. Pharmaceutics 2021, 13, 594. [Google Scholar] [CrossRef]
  144. Sharifi, F.; Simbar, M.; Mojab, F.; Majd, H.A. Comparison of the effects of Matricaria chamomila (Chamomile) extract and mefenamic acid on the intensity of premenstrual syndrome. Complement. Ther. Clin. Pract. 2014, 20, 81–88. [Google Scholar] [CrossRef]
  145. Ozgoli, G.; Selselei, E.A.; Mojab, F.; Majd, H.A. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J. Altern. Complement. Med. 2009, 15, 845–851. [Google Scholar] [CrossRef]
  146. Roy, P.; Khar, P.; Karia, S.; Shah, N.; Desousa, A. Effect of psychotropics on bleeding and clotting factors. Acta Haematol. Pol. 2022, 53, 392–397. [Google Scholar] [CrossRef]
  147. Bahrampour, N.; Mirzababaei, A.; Yarizadeh, H.; Barekzai, A.; Khorsha, F.; Clark, C.; Mirzaei, K. The relationship between dietary nutrients patterns and intensity and duration of migraine headaches. Br. J. Nutr. 2023, 129, 947–954. [Google Scholar] [CrossRef]
  148. Rock, C.L.; Gorenflo, D.W.; Drewnowski, A.; Demitrack, M.A. Nutritional characteristics, eating pathology, and hormonal status in young women. Am. J. Clin. Nutr. 1996, 64, 566–571. [Google Scholar] [CrossRef]
  149. Al-Shahrani, A.M.; Miskeen, E.; Shroff, F.; Elnour, S.; Algahtani, R.; Youssry, I.; Ahmed, S. Premenstrual Syndrome and Its Impact on the Quality of Life of Female Medical Students at Bisha University, Saudi Arabia. J. Multidiscip. Healthc. 2021, 14, 2373–2379. [Google Scholar] [CrossRef]
  150. Kahyaoglu Sut, H.; Mestogullari, E. Effect of Premenstrual Syndrome on Work-Related Quality of Life in Turkish Nurses. Saf. Health Work 2016, 7, 78–82. [Google Scholar] [CrossRef]
  151. İşik, H.; Ergöl, Ş.; Aynioğlu, Ö.; Şahbaz, A.; Kuzu, A.; Uzun, M. Premenstrual syndrome and life quality in Turkish health science students. Turk. J. Med. Sci. 2016, 46, 695–701. [Google Scholar] [CrossRef] [PubMed]
  152. Farrokh-Eslamlou, H.; Oshnouei, S.; Heshmatian, B.; Akbari, E. Premenstrual syndrome and quality of life in Iranian medical students. Sex. Reprod. Healthc. 2015, 6, 23–27. [Google Scholar] [CrossRef] [PubMed]
  153. Câmara, R.A.; Köhler, C.A.; Frey, B.N.; Hyphantis, T.N.; Carvalho, A.F. Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool (PSST) and association of PSST scores with health-related quality of life. Braz. J. Psychiatry 2017, 39, 140–146. [Google Scholar] [CrossRef]
  154. Victor, F.F.; Souza, A.I.; Barreiros, C.D.T.; Barros, J.L.N.; Silva, F.A.C.D.; Ferreira, A.L.C.G. Quality of Life among University Students with Premenstrual Syndrome. Rev. Bras. Ginecol. Obstet. 2019, 41, 312–317. [Google Scholar] [CrossRef] [PubMed]
  155. Jaber, R.M.; Alghzawi, A.O.; Salameh, H.H. Premenstrual syndrome: Consultation sources and the impact on women’s quality of life. Afr. Health Sci. 2022, 22, 80–87. [Google Scholar] [CrossRef]
  156. Karimiankakolaki, Z.; Mazloomy Mahmoodabad, S.S.; Heidari, F.; Gerayllo, S.; Khabiri, F. The Relationship between Premenstrual Syndrome and Women’s Marital Satisfaction. J. Midw. Reprod. Health 2019, 7, 1650–1655. [Google Scholar]
  157. Hardy, C.; Hardie, J. Exploring premenstrual dysphoric disorder (PMDD) in the work context: A qualitative study. J. Psychosom. Obstet. Gynaecol. 2017, 38, 292–300. [Google Scholar] [CrossRef] [PubMed]
  158. Hardy, C.; Hunter, M.S. Premenstrual Symptoms and Work: Exploring Female Staff Experiences and Recommendations for Workplaces. Int. J. Environ. Res. Public Health 2021, 18, 3647. [Google Scholar] [CrossRef] [PubMed]
  159. Heinemann, L.A.; Minh, T.D.; Filonenko, A.; Uhl-Hochgräber, K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. Women’s Health Issues 2010, 20, 58–65. [Google Scholar] [CrossRef] [PubMed]
  160. Jeon, B.; Baek, J. Menstrual disturbances and its association with sleep disturbances: A systematic review. BMC Women’s Health 2023, 23, 470. [Google Scholar] [CrossRef] [PubMed]
  161. Prasad, D.; Wollenhaupt-Aguiar, B.; Kidd, K.N.; de Azevedo Cardoso, T.; Frey, B.N. Suicidal Risk in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Systematic Review and Meta-Analysis. J. Women’s Health 2021, 30, 1693–1707. [Google Scholar] [CrossRef]
  162. Yan, H.; Ding, Y.; Guo, W. Suicidality in patients with premenstrual dysphoric disorder—A systematic review and meta-analysis. J. Affect. Disord. 2021, 295, 339–346. [Google Scholar] [CrossRef]
Nutrients 16 01911 g001
Figure 1. Potential treatment options for women with PMS. Abbreviations: SSRI—selective serotonin reuptake inhibitors, COCs—combined oral contraceptives.
Figure 1. Potential treatment options for women with PMS. Abbreviations: SSRI—selective serotonin reuptake inhibitors, COCs—combined oral contraceptives.
Nutrients 16 01911 g001
Table 1. The studies assessed the associations between macronutrient intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
Table 1. The studies assessed the associations between macronutrient intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
AuthorMethods of Diet AnalysisCharacteristics of PopulationType of StudyResults
Hashim, Mona et al. [48], 2019Self-administered, semi-quantitative food-frequency questionnaire (FFQ)300 Arabian women
(95% with at least one PMS symptom)		cross-sectional studyHigh fat, sugar, and salt intake was associated with an increased risk of physical symptoms of PMS (OR = 3.2, 95% CI 1.4–7.3; p < 0.05)
Farasati et al.
[49] 2015		Self-administered, semi-quantitative food-frequency questionnaire (FFQ)320 Iranian nurses
(160 with and 160 without PMS)		case-control studyA significant association between the Western dietary pattern and PMS was shown.
In participants in the second and third quartiles of the Western dietary pattern, PMS occurred more frequently than in women in the first quartile (OR = 2.53; 95% CI = 1.18, 5.43; OR = 4.39; 95% CI 1.97, 9.81, respectively). The relationship remained significant after adjustment for age, BMI, menstrual cycle status, physical activity and energy intake (OR = 2.53; 95% CI 1.18, 5.43 and OR = 4.39; 95% CI 1.97, 9.81, respectively)
Thakur et al. [51], 20223-day food diary including one weekend day and 70 food items FFQ330 Indian women
(46.9% with mild PMS, 31.5% with moderate PMS, 8.3% with severe PMS, and 13.3% without PMS symptoms)		observational studyLactovegetarians and ovolactovegetarian women experienced milder PMS symptoms than women who consumed a non-vegetarian diet. The energy consumption and protein, dietary fiber, calcium, iron, vitamin C, and vitamin B12 levels were lower than the recommended dietary allowance (RDA). Carbohydrate intake was slightly higher, and fat was significantly higher than that of RDA.
A significant correlation between PMS and the consumption of sweets, fried savory foods, and fast foods was found.
An inverse association between oilseed consumption and PMS was shown.
Taheri,
et al. [54], 2023		147 food items FFQ223 Iranian women
(25% with PMS)		cross-sectionalTotal fat and sugar intake were associated with PMS.
MoradiFili, et al. [55], 2020Self-administered, semi-quantitative food-frequency questionnaire (FFQ)559
(225 Iranian women with PMS and 334 healthy controls aged 20–45 years		case-control studyA significant association was observed between the Western dietary pattern (high intake of fast foods, soft drinks, and processed meats) and PMS. PMS occurred frequently in participants in the highest tertile of the Western diet patterns (OR = 1.49; 95% CI 1.01, 3.52), p < 0.001).
A negative correlation between healthy (rich in dried fruits, condiments, and nuts) and traditional (rich in eggs, tomato sauce, fruits, and red meat) dietary patterns and PMS was found (OR = 0.31; 95% CI: 0.17, 0.72, p = 0.02; OR = 0.33; 95% CI: 0.14, 0.77, p = 0.01, respectively).
Houghton et al. [47], 2018131-item FFQ at baseline and every four years during follow-up116,429 American nurses aged 25–42 years
(during observation
4108 new diagnoses of PMS)		prospective cohort study with
14 years of follow-up		Maltose intake at 14 years of age was linearly associated with the risk of PMS (p for trend = 0.005). The highest intake (median = 3.0 g/day) was associated with a 45% higher risk of developing PMS than the lowest intake (median = 1.2 g/day) (95% CI = 1.11–1.88).
Houghton et al. [56], 2017131-item semi-quantitative FFQ3660 American women baselines without PMS aged 25–42 years (during observation 1234 with and
2426 without PMS)		prospective cohort study with
14 years of follow-up		High SFA intake, especially stearic acid, was associated with lower PMS risk (relative risk (RR) quintile 5 (median = 28 · 1 g/d) vs. quintile 1 (median = 15 · 1 g/d) = 0 · 75; 95% CI 0 · 58, 0 · 98; p for trend = 0 · 07).
Table 2. The studies assessed the associations between micronutrient intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
Table 2. The studies assessed the associations between micronutrient intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
AuthorMethodsCharacteristics of PopulationType of StudyResults
Quaglia et al. [44], 2023food diaries30 Italian women aged 19–49 years
(16 with PMS)		observational studycopper intake was significantly higher in women with PMS.
Taheri et al. [54], 2023147-item FFQ223 Iranian women
(25% with PMS)		retrospective cross-sectional studysodium intake was associated with an increased risk of the development of PMS
Thys-Jacobs et al. [60], 1998Supplementation of 1200 mg calcium carbonate or placebo466 premenopausal women
(231 patients treated with calcium and 235 with the placebo)		A Multicenter clinical trialno significant differences between groups in the mean screening symptom complex score of the luteal, menstrual, or intermenstrual phase of the menstrual cycle were found
A significantly lower mean symptom complex score was observed in the group treated with calcium for both the second (p = 0.007) and third (p < 0.001) treatment cycles
Saeedian et al. [59], 201524-h food recall questionnaire62 Iranian young women
(31 with PMS)		case-control studycalcium, magnesium and potassium intake were lower in the PMS group
Chocano-Bedoya et al. [61], 2013food frequency questionnaires completed in 1991, 1995, and 19991057 American women with PMS and
1968 without
PMS at baseline		prospective case-control study with 10 years of follow-upThe highest quintile of nonheme iron intake was associated with a 64% RR of PMS (95% CI 0.44, 0.92; p for trend = 0.04).
The highest quintile of potassium intake was associated with 146% RR of PMS (95% CI: 0.99, 2.15; p for trend = 0.04).
Ahmadi et al. [63], 2023220 mg elemental zinc or placebo supplementation daily for 24 weeks69 young Iranian women
(35 with PMS)		randomized clinical trialZinc supplementation significantly decreases physical and psychological symptoms of
PMS.
Jafari et al. [64], 202030 mg zinc gluconate or placebo supplementation daily for 12 weeks60 Iranian women aged 18–30 years with PMSrandomized clinical trialZinc supplementation significantly decreases physical (p < 0.05) and psychological (p < 0.001) symptoms of
PMS.
Table 3. The studies assessed the associations between vitamin intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
Table 3. The studies assessed the associations between vitamin intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
AuthorMethods Characteristics of PopulationType of StudyResults
Chocano-Bedoya et al. [65], 2011FFQ at the baseline and twice after 4 and 8 years3025 American women without PMS at the baseline (1968 controls and 1057 with PMS after 10 years)case-control studyAn inverse relationships between the occurrence of PMS and thiamine and riboflavin intake were found.
Retallick-Brown et al. [66], 2020Supplementation with 80 mg daily vitamin B6 or micronutrients during three menstrual cycles78 women with PMSpilot randomized treatment-controlled trial72% of the micronutrient and 60% of the vitamin B6 group achieved complete remission in PMS symptoms.
Abdollahifard et al. [68], 2014Supplementation with 100 mg daily thiamine or placebo one pill in the morning and one pill at night or placebo during one week before menstruation for three consecutive menstrual cycles80 Iranian women with PMS aged 18–30 yearsdouble-blind placebo-controlled clinical trial
randomization 1:1		Thiamine supplementation reduces by 35.08% mental symptoms and by 21.2% physical symptoms of PMS.
Samieipour et al. [69], 2016Supplementation with 100 mg thiamine or 500 mg calcium carbonate or both or placebo once daily from one week before menstruation to 4 days after menstruation for two consecutive menstrual cycles264 Iranian women with PMS aged 18–30 yearsrandomized controlled trial randomization 1:1:1:1Supplementation with thiamine decreased PMS symptoms more than placebo.
Supplementation with calcium decreased PMS symptoms more than thiamine and placebo.
The reduction symptoms of PMS in the group supplemented with both thiamine and calcium were higher than in the other groups.
Bertone-Johnson et al. [70], 2005assessment of vitamin D intake using FFQ at the baseline and during 4 and 8 years of the follow-up3025 American women aged 27–44 years without PMS at baseline (1968 controls and 1057 with PMS)prospective case-control study with 10 years of follow-upHigh vitamin D intake was associated with a lower risk of the development of PMS [RR 0.59 (95% CI, 0.40–0.86).
Bertone-Johnson et al. [72], 2010FFQ44 American
women aged 18–30 years meeting standard criteria for PMS and 46 women meeting control criteria		cross-sectional studyNo significant inverse relationship between vitamin D intake from food sources and the severity of PMS symptoms was found.
Rajaei et al. [73], 2016Levels of 25 hydroxy-vitamin D3 (25OHD) were determined by ELISA in the luteal phase82 Iranian women aged 18–40 yearscase-control studyNo significant relationship between the severity of PMS symptoms and the vitamin D levels was shown.
Bahrami et al. [74], 2018Supplementation with nine high-dose vitamin D (50,000 IU/week of cholecalciferol)897 Iranian adolescent girls (14.9% with PMS)clinical trialThe occurrence of PMS after the intervention decreased from 14.9% to 4.8% (p < 0.001).
Tartagni et al. [75], 2016Treatment with 200,000 IU first, followed by 25,000 IU every 2 weeks, or placebo for 4 months.158 Italian girls
(78 placebo group, 80 vitamin-D group)		randomized controlled clinical trialTreatment with vitamin D reduces significantly anxiety, irritability, ease of crying and sadness as well as significantly improves disturbed interpersonal relationships.
Karimi et al. [76], 2018Four groups: cognitive–behavioral therapy; supplementation 500 mg calcium and 200 IU vitamin D; cognitive–behavioral therapy + supplementation 500 mg calcium and 200 IU vitamin D; the lack of intervention for 8 weeks40 Iranian women aged 22–48 yearsquasi-experimental randomization 1:1:1:1Significant improvement in PMS symptoms in the group treated with calcium plus vitamin D together with CBT than in the other groups.
Khajehei et al. [77], 2009Three groups: treated with 5 mg of dydrogesterone or supplemented with 500 mg of calcium plus 200 mg of vitamin D, or placebo twice daily from the 15th to the 24th day of the cycle for 2 menstrual cycles180 Iranian young women with PMSrandomized, double-blind, placebo-controlled studyTreatment with dydrogesterone or calcium plus vitamin D similarly decreased severity of PMS symptoms (by 4.64% and 4.20%, respectively) and placebo by 3.42%.
The greatest effects were observed in loss of concentration, disturbed interpersonal relationships, anxiety, and arthralgia.
Dadkhah et al. [78], 2016Supplementation with 200 mg of vitamin D, or 100 mg of vitamin E, or a placebo each day during 2 consecutive menstrual cycles86 Iranian women with PMS aged 15–45 yearsrandomized controlled trialThe mean score of the syndrome significantly decreased in all three groups. However, there were no differences between groups.
Table 4. The studies assessed the associations between other nutrient intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
Table 4. The studies assessed the associations between other nutrient intake and premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD).
AuthorMethodsCharacteristics of PopulationType of StudyResults
Schmidt et al. [80], 2018Supplementation with 400 mg lecithin-
phosphatidylserine and 400 mg
phosphatidic acid or placebo for 3 menstrual cycles		40 women with PMS aged 18–45 yearsrandomized controlled trialThe study supplements significantly more than placebo reduce PMS physical symptoms severity and depression.
Rossignol et al. [82], 1985caffeine-containing beverages including coffee, tea and cola intake295 American college sophomoresquestionnaire-based studyA relationship between the consumption of caffeine-containing beverages and the occurrence and severity of PMS was found.
Rossignol et al. [87], 1990caffeine-containing beverages including coffee, tea and cola intake841 American studentsquestionnaire-based studydose-dependent relationship between the consumption of caffeine-containing beverages and the occurrence of PMS (OR = 1.3 for consumers of one cup of caffeine-containing beverages per day, OR = 7.0 for consumers of 8 to 10 cups per day)
Rasheed et al. [89], 2003Participants indicated the type of caffeinated beverage consumed from a list including cola drinks, tea, cocoa chocolates and coffee, including the Arab coffee “Gahwa”. 464 Saudi Arabian women aged 17–27 yearsquestionnaire-based studyA relationship between the consumption of caffeinated, coffee (especially over 7 cups per week) and the severity of PMS symptoms was found.
Purdue-Smithe et al. [93], 2016Caffeine, coffee, and tea intake was assessed using food-frequency questionnaires every 4 years1234 women with PMS, 2426 controlscase-control study nested within the prospective Nurses’ Health Study IIThere was no association between the risk of the development of PMS or its specific symptoms and total caffeine intake.
Sayegh et al. [94], 1995Supplementation with the specially formulated carbohydrate-rich beverage compared with two other isocaloric24 women with PMSdouble-blind, crossover studyThe reduction of psychological symptoms of PMS and appetite can be obtained by specially formulated carbohydrate-rich beverage intake
Table 5. These studies assessed the impact of PMS on quality of life, interpersonal relationships, and work productivity.
Table 5. These studies assessed the impact of PMS on quality of life, interpersonal relationships, and work productivity.
AuthorCohortPrevalence of PMS (%)Adverse Outcomes
Al-Shahrani et al. [149], 2021338 female Saudi Arabian medical students64.9%PMS significantly influenced daily activities related to quality of life and homework as well as their learning environment.
Kahyaoglu et al. [150], 2016134 Turkish nurses38.1%All of the WRQoL subscale scores except stress at work were significantly lower in the group with than without PMS.
İşik et al. [151], 2016608 Turkish health sciences students84.5%The quality of life decreases with the severity of PMS.
Farrokh-Eslamlou et al. [152], 2015142 Iranian female medical students39.4% including 60.6% with mild, 25.1% with moderate and 14.2% with severe PMSThe quality of life score means in mental health (p = 0.02) and environmental health decreases as the PMS score average increases.
PMS has adverse effects on academic performance and related quality of life.
Câmara et al. [153], 2017801 Brasilian women aged 18 years and over39.7% with moderate to severe PMS
16.5% with PMDD		Physical, psychological and social domain quality of life decreased with the severity of PMS/PMDD.
Victor et al. [154], 2019642 Brasilian female students aged 18–24 years49.9% including
23.3% with mild PMS and 26.6% with PMDD		Both physical and mental domains of WHOQL-Bref were significantly lower in women with mild PMS and PMDD than without PMS.
Social relationships and environmental domains were significantly lower in women with mild PMS than in those without PMS.
Jaber et al. [155], 2022179 Jordanian women aged 20–30 years88%PMS affects daily activities, satisfaction with general appearance and weight and relationships with family members and other people.
Karimiankakolaki et al. [156], 2019246 Iranian women aged 15–49 years87.4%The effect of PMS on daily life was stronger in terms of relationships with family. In addition, marital dissatisfaction was higher among women with PMS than without PMS.
Hardy et al. [158], 2021125 working women from UK40% with moderate to severe symptoms of PMSSevere PMS symptoms were significantly associated with poor presenteeism, intention to reduce working hours, and higher work absence (time off work, being late, leaving early).
Moderate/severe symptoms were significantly associated with poorer work-life balance, lower levels of psychological resilience, higher perceived work demands, and less control over work.
Heinemann et al. [159], 2010822 German women aged 15–45 years56.7% with mild PMS
30.25% with moderate to severe PMS
4.9% with PMDD		Employed women with moderate to severe PMS/PMDD had a higher rate of productivity impairment than those with no perceived symptoms/mild PMS (adjusted OR, 3.12; 95% CI: 1.75–5.57).
Women with moderate to severe PMS/PMDD had a higher rate of absenteeism (>8 h per cycle; 14.2% vs. 6.0%).
Jeon et al. [160], 2023a systematic review of 35 studies including 26,867 women PMS was associated with sleep disturbances including satisfaction, alertness during waking hours, efficiency and duration.
Prasad et al. [161], 2021systematic review and meta-analysis of 13 studies including 12,929 women Women with PMDD are almost seven times at higher risk of suicide attempt (OR: 6.97; 95% CI: 2.98–16.29, p < 0.001) and almost four times as likely to exhibit suicidal ideation (OR: 3.95; 95% CI: 2.97–5.24, p < 0.001). Women with PMS have also an increased risk of suicidal ideation (OR: 10.06; 95% CI: 1.32–76.67, p = 0.03), but not suicide attempts (OR: 1.85; 95% CI: 0.77–4.46, p = 0.17)
Yan et al. [162], 2021meta-analysis of 6 studies including 8532 women PMDD was associated with an increased risk of:
-
suicidal ideation (OR = 2.34, 95% CI: 1.50–3.18, p = 0.99),
-
experiencing suicide attempt (OR = 2.13, 95% CI: 1.05–3.21, p = 0.81),
-
suicidal plan (OR = 2.24, 95% CI: 1.03–3.45, p = 0.96).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Oboza, P.; Ogarek, N.; Wójtowicz, M.; Rhaiem, T.B.; Olszanecka-Glinianowicz, M.; Kocełak, P. Relationships between Premenstrual Syndrome (PMS) and Diet Composition, Dietary Patterns and Eating Behaviors. Nutrients 2024, 16, 1911. https://doi.org/10.3390/nu16121911

AMA Style

Oboza P, Ogarek N, Wójtowicz M, Rhaiem TB, Olszanecka-Glinianowicz M, Kocełak P. Relationships between Premenstrual Syndrome (PMS) and Diet Composition, Dietary Patterns and Eating Behaviors. Nutrients. 2024; 16(12):1911. https://doi.org/10.3390/nu16121911

Chicago/Turabian Style

Oboza, Paulina, Natalia Ogarek, Mariusz Wójtowicz, Tahar Ben Rhaiem, Magdalena Olszanecka-Glinianowicz, and Piotr Kocełak. 2024. "Relationships between Premenstrual Syndrome (PMS) and Diet Composition, Dietary Patterns and Eating Behaviors" Nutrients 16, no. 12: 1911. https://doi.org/10.3390/nu16121911

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop